Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Microbiome of the Eye01:22

Microbiome of the Eye

The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polymyalgia Rheumatica. Reply.

The New England journal of medicine·2026
Same author

The Global Rheumatology Workforce: Challenges and Considerations.

Rheumatic diseases clinics of North America·2026
Same author

A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.

Seminars in arthritis and rheumatism·2026
Same author

Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Recommendations of the German, Austrian and Swiss rheumatology and other medical societies for the management of polymyalgia rheumatica.

Rheumatology (Oxford, England)·2025
Same author

Confounding by indication in observational studies investigating glucocorticoid-associated adverse events in patients with rheumatoid arthritis: a systematic literature review including an assessment of E-values.

Annals of the rheumatic diseases·2025
Same journal

Orbital Inflammatory Syndrome Associated with Bispecific T-Cell Engager Therapy: Case and Literature Review.

Ophthalmic plastic and reconstructive surgery·2026
Same journal

A Rare Pedunculated Lobular Capillary Hemangioma of the Conjunctiva.

Ophthalmic plastic and reconstructive surgery·2026
Same journal

Core Oculoplastic Procedure Skills for the Comprehensive Ophthalmologist: A Consensus by Delphi Methodology.

Ophthalmic plastic and reconstructive surgery·2026
Same journal

The Role of Corneal Sensation in Facial Nerve Paralysis.

Ophthalmic plastic and reconstructive surgery·2026
Same journal

Lacrimal Gland Dacryolithiasis With Secondary Bacterial Dacryoadenitis: Clinicoradiological Characterization and Review of Literature.

Ophthalmic plastic and reconstructive surgery·2026
Same journal

Aprepitant for Oculoplastic Surgeries.

Ophthalmic plastic and reconstructive surgery·2026
See all related articles

Related Experiment Videos

Biologic response modifiers for ophthalmologists

James A Garrity1, Eric L Matteson

  • 1Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA. garrity.james@mayo.edu

Ophthalmic Plastic and Reconstructive Surgery
|September 23, 2008
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos